Why ANNX rose on Oct 19
Up 18% on Oct 19, and still 24% over its Oct 16 close.
- Annexon rose 18% that day while small-cap biotech stocks rose a median 2%:
The other side, the timeline, and its peers, for Pro members.
Annexon (ANNX) stock
$4.21
Quality Score
-6
In its industry
#84of 90
Checks firing
1of 14
From 52-week high
-41.4%
ANNX's Quality Score fell 1 point on Tue, Nov 10, to -6. It did not trade higher than the day before.
Follow ANNX's trial news. Pro members can get an alert when Annexon files news, and see its trials, share raises, and its CEO's filings.
Get an alert when ANNX files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
NextQ4 2026“…(DMC) will assess the ARCHER II single study Month 15 primary endpoint in the fourth quarter of 2026…”
Cash$213M, about 4 quarters at the last year's spending
Key facts on ANNX
| Holding it back | 37.2% more shares than a year ago |
| Latest filing | 8-K, Nov 9 |
1 more reason behind ANNX's -6, free with an account →3 more reasons behind ANNX's -6, for Pro members.
ANNX in the news
ReportLast night: the results are out. Past reports ›
Cash$213M, about 4 quarters at the last year's spending
ANNX catalysts
Coming up
After its last 4 reports it closed +3.5% on average, higher 2 of 4 times.
What's next for ANNX, and how long its cash lasts
Next step the company has named
Q4 2026“An independent Data Monitoring Committee (DMC) will assess the ARCHER II single study Month 15 primary endpoint in the fourth quarter of 2026.”
Cash runway
About 4 quarters
Dilution on the horizon
- Shelf registration (S-3ASR, filed Mar 31, 2026)
- At-the-market share sales program (S-3ASR, filed Mar 31, 2026)
Insiders
CEO Douglas Love bought 26,065 shares on Sep 24. 14 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Why ANNX scores -6
Poorfor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means
- −2Long-term trend below a falling 200-day average, down over two years
- −2Dilution 37.2% more shares outstanding than a year ago
- Chart checks adds
- Profit subtracts
- Volatility subtracts
- Cash flow subtracts
What every line is worth, and the reason behind it, on ANNX and every other stock.Get in free →
How ANNX ranks in Pharma
ANNX is #84 of 90 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 84 |
Share count against a year before: ANNX +37%, LXRX +22%.
When does ANNX report earnings, and what happens after?
Expected to report Mon Mar 29, after the close (in 139 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
What ANNX reported on Nov 9, 2026
The quarter
The figures are not read from the release yet.
“The change in G&A expenses reflects ongoing corporate consulting and professional services costs for the advancement of our registrational programs and compensation and personnel-related expenses.”
Where the sales came from
ANNX's results filing gives no sales by line in a table we read.
The outlook
No outlook figures read from this release.
In the company's words
“Next Milestone: EMA review of MAA underway; BLA submission with U.S./European data from FORWARD expected fourth quarter of 2026.”
From its results filing (SEC filing · Nov 9)
The numbers
- $759M
- today
- -$190M
- last 12 months
Close after the report, last 3
+3.1%-0.2%-0.5%
May 7Aug 12Nov 9
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 9, 2026 | +1.6% | -0.5% | not yet |
| Aug 12, 2026 | -5.2% | -0.2% | -1.1% |
| May 7, 2026 | +1.7% | +3.1% | -2.7% |
ANNX has 1 of 14 chart checks firing
The other 10 checks on ANNX, and all 14 on every stock.Get in free →
ANNX RSI today: 54.7, above its 50-day, below its 200-day
RSI 54.7, MACD above signal, above its 50-day, below its 200-day. Not scored.
The deep dive on ANNX
- What it does and how it makes money
- Where it standsSEC filing · Nov 13, 2025
- Who holds and trades it
- Against its closest peers
ANNX insider trades
2 insiders bought $3.4M across 2 filings in the last 6 months. No open-market sales on record. The newest:
BuyDouglas Love$100K
ANNX's officers and directors
Officers and directors with a Form 4 in the last 12 months.
Which ETFs hold ANNX?
In ETFs: ANNX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
About Annexon
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
Pro members see every line of every stock's score.
- What would turn ANNX's score around: 8 things
- 8 more filings explained, a plain line each
- Real-time prices, no delay
BreakawaySep 25Douglas Love bought ANNX
Straight AnswersStraight Answers
What does ANNX's Quality Score say?
ANNX scores -6 today, which Breakaway calls Poor. It is #84 of 90 in Pharma by Quality Score, with 1 of 14 chart checks firing. Up 18% on Oct 19, and still 24% over its Oct 16 close. Cash lasts about 4 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
What is ANNX's Quality Score?
ANNX scores -6 today, which Breakaway calls Poor (below zero). That is #84 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ANNX's -6.
Are insiders buying ANNX?
2 insiders bought $3.4M across 2 filings in the last 6 months. No open-market sales on record. The newest is Douglas Love, President and CEO, who bought $100K on Sep 24. Every filing, with the scored weight, for Pro members.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.